Understanding drugs and diseases by systems biology?

被引:17
|
作者
Schneider, Hans-Christoph [1 ]
Klabunde, Thomas [1 ]
机构
[1] Sanofi Aventis Deutsch GmbH, Computat Biol & Bioinformat, Design & Informat FF, R&D LGCR Struct, D-65926 Frankfurt, Germany
关键词
Systems biology; Molecular mechanistic models; Physiological models; Top-down systems biology; Bottom-up systems biology; MODEL; SIMULATION; GENERATION; PREDICTION; DISCOVERY; NETWORKS; DATABASE; ERBB3;
D O I
10.1016/j.bmcl.2012.12.031
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Systems biology aims to provide a holistic and in many cases dynamic picture of biological function and malfunction, in case of disease. Technology developments in the generation of genome-wide datasets and massive improvements in computer power now allow to obtain new insights into complex biological networks and to copy nature by computing these interactions and their kinetics and by generating in silico models of cells, tissues and organs. The expectations are high that systems biology will pave the way to the identification of novel disease genes, to the selection of successful drug candidates-that do not fail in clinical studies due to toxicity or lack of human efficacy-and finally to a more successful discovery of novel therapeutics. However, further research is necessary to fully unleash the potential of systems biology. Within this review we aim to highlight the most important and promising top-down and bottom-up systems biology applications in drug discovery. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1168 / 1176
页数:9
相关论文
共 50 条